NEW YORK, Dec. 13, 2020 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of
novel cancer immunotherapies for a broad range of cancer indications, today announced that it has entered into a share purchase agreement with institutional investors to purchase approximately